Cargando…
Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapy
Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients. Soluble interleukin-2 receptor (sIL-2R) levels at diagnosis are prognostic...
Autores principales: | Shirouchi, Yuko, Nishimura, Noriko, Mishima, Yuko, Ishihara, Yuko, Asai, Hiroaki, Tamba, Mikako, Hirano, Mitsuhito, Hirano, Kei, Teramoto, Yukako, Yoshida, Kikuaki, Takeuchi, Kengo, Terauchi, Takashi, Maruyama, Dai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444791/ https://www.ncbi.nlm.nih.gov/pubmed/37608029 http://dx.doi.org/10.1038/s41598-023-40026-7 |
Ejemplares similares
-
PB2317: POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB THERAPY IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-INSTITUTION EXPERIENCE FOCUSING ON DETAILED ASSESSMENT OF TOXICITIES
por: Hirano, Mitsuhito, et al.
Publicado: (2023) -
P1106: CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY.
por: Hirano, Kei, et al.
Publicado: (2023) -
Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
por: Hirano, Mitsuhito, et al.
Publicado: (2022) -
Extramedullary Plasmacytoma Mimicking Gallbladder Cancer
por: Nishimura, Noriko, et al.
Publicado: (2022) -
Diffuse large B‐cell lymphoma arising immediately after completion of treatment for Hodgkin lymphoma
por: Hirota, Ai, et al.
Publicado: (2021)